X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
MTX652 is a potent and selective compound designed to improve mitochondrial quality and function by enhancing mitophagy through inhibition of USP30 enzyme. It is being evaluated for the treatment of acute kidney injury (AKI) following cardiac surgery.
Lead Product(s): MTX652
Therapeutic Area: Nephrology Product Name: MTX652
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2023
Details:
MTX325 is a USP30 inhibitor small molecule drug candidate, which is currently being evaluated in clinical trial studies with patients for the treatment of parkinson's disease.
Lead Product(s): MTX325
Therapeutic Area: Neurology Product Name: MTX325
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2023
Details:
MTX652 potently and specifically inhibits USP30 with the aim of enabling appropriate degradation of dysfunctional mitochondria to preserve overall mitochondrial quality and improve cellular health.
Lead Product(s): MTX652
Therapeutic Area: Genetic Disease Product Name: MTX652
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Details:
Mission has developed MTX652 to inhibit USP30 with the aim to enable appropriate degradation of dysfunctional mitochondria to preserve and improve cellular health. Mission is also investigating the potential of USP30 inhibitors to treat these diseases.
Lead Product(s): MTX652
Therapeutic Area: Nephrology Product Name: MTX652
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2022
Details:
The research grant will support testing of Mission’s lead CNS-penetrant USP30 DUB inhibitors in an in vivo model of Familial Parkinson’s Disease (PD), as well as ongoing preclinical development towards candidate selection.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Michael J. Fox Foundation
Deal Size: $0.5 million Upfront Cash: Undisclosed
Deal Type: Financing October 12, 2021
Details:
Under the terms of the agreement, first announced in 2018, Mission and AbbVie are collaborating to identify novel DUB targets and discover associated inhibitor compounds for neurodegenerative diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: $20.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration August 09, 2021
Details:
The new capital will support development of Mission’s world-leading DUB platform, as well as growth of its pipeline of DUB inhibitor programmes.
Lead Product(s): Undisclosed
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Financing July 06, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
